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Abstract 
Introduction: We sought to compare clinical and imaging mismatch treatment selection 
criteria in a pooled cohort from randomised trials of intravenous tenecteplase vs alteplase 
where CT perfusion (CTP) was performed prior to treatment. Methods: Baseline clinical and 
imaging scores were used to categorise patients as meeting either the DAWN mismatch 
(baseline NIHSS =>10, and age cut offs for ischemic core volume) or DEFUSE 2 mismatch 
criteria (CTP mismatch volume >15mL, mismatch ratio >1.8 and ischemic core <70mL). We 
then investigated whether tenecteplase treated patients had favourable odds of less disability 
(on the modified Rankin scale, mRS) compared to those treated with alteplase, for clinical 
and imaging mismatch classifications respectively. Results: From 146 pooled patients, 71 
received alteplase and 75 received tenecteplase. The overall pooled group did not show 
improved patient outcomes when treated with tenecteplase (mRS 0-1 OR 1.77, 95% CI 0.89-
3.51, p=0.102) compared with alteplase. A total of 39 (27%) patients met both the clinical 
and imaging mismatch criteria, 25 (17%) patients met only the imaging criteria, 36 (25%) 
met only the clinical mismatch criteria and, finally, 46 (31%) did not meet either of the 
imaging or mismatch criteria. Patients treated with tenecteplase had more favourable 
outcomes when they met either imaging mismatch (mRS 0-1, OR 2.33, 95% CI 1.13-5.94, 
p=0.032) or clinical mismatch criteria (mRS 0-1, OR 2.15, 95% CI 1.142, 8.732, p=0.027) 
but with differing proportions. Conclusion: Target mismatch selection was more inclusive 
(hence more generalizable) and exhibited in a larger treatment effect between tenecteplase 
and alteplase.  
 
  
Introduction 
The exact selection criteria of patients with ischemic stroke for therapy with either 
thrombolysis or thrombectomy remains a controversial topic.1 As time progresses, there are 
more trials being completed with varying inclusion and exclusion criteria, such as the DAWN 
trial which required a mismatch between clinical deficit and age-based ischemic core 
volumes. The EXTEND IA, DEFUSE 3 and Australian tenecteplase trials required target 
(perfusion-core) mismatch in patients with a large vessel occlusion, whereas the ATTEST 
and IST3 trials did not require any tissue-based imaging selection. Importantly, the statistical 
evidence supporting the validity of these varying imaging or clinical inclusion/exclusion 
criteria is difficult to directly compare or lacking. It is a challenge to determine which 
imaging method is superior to the others in terms of best identifying reperfusion therapy 
responders and excluding those who are either likely to be harmed or who have a good 
natural history regardless of treatment. Therefore, in the present study, we sought to 
investigate the effect of clinical and imaging-based mismatch criteria on outcomes of a 
pooled dataset of randomised clinical trials of ischemic stroke where patients received either 
intravenous tenecteplase or alteplase. We previously showed that applying standard clinical 
and non-contrast CT based selection criteria for thrombolysis did not allow detection of a 
clinical outcome difference for tenecteplase compared to alteplase treated patients, despite 
more effective reperfusion seen with tenecteplase.2 We hypothesized that both clinical-core 
mismatch and target (perfusion-core) mismatch imaging selection criteria would translate the 
enhanced reperfusion from tenecteplase into better clinical outcomes, but that the two 
different mismatch selection criteria would include different patients, and hence lead to 
different treatment effect sizes.3 
 
Methods 
 For this study we pooled data from the Australia-TNK and Alteplase versus 
tenecteplase for thrombolysis after ischaemic stroke (ATTEST) trials. 
Trials description 
The Australia-TNK and ATTEST trials were Prospective, Randomised, Open, 
Blinded End-point (PROBE) studies comparing the efficacy and safety of alteplase and 
tenecteplase in thrombolysis-eligible patients with acute ischaemic stroke, using clinical and 
imaging biomarkers for outcome evaluation. The Australia-TNK study recruited from three 
sites and ATTEST was a single centre study. For both studies, patients were eligible if they 
had a clinically diagnosed supratentorial acute ischaemic stroke with a measurable deficit on 
the NIH stroke scale (NIHSS), were aged ≥18 years, were living independently pre-stroke, 
and were considered eligible for intravenous thrombolysis according to local clinical 
guidelines. Both studies included patients over 80 years of age. Both trials excluded patients 
with major early ischemic change on non-contrast CT (NCCT). In ATTEST, patients had to 
be presenting to hospital within 4.5 hours of symptom onset, and in the Australian study 
patients were included up to 6 hours post-onset. In ATTEST, patients were randomised to 
either tenecteplase 0.25mg/kg or alteplase 0.9mg/kg treatment on a 1:1 basis. The Australia-
TNK trial randomised patients to alteplase 0.9mg/kg or one of two doses of tenecteplase (0.1 
mg/kg or 0.25 mg/kg) on a 1:1:1 basis. This analysis pooled trial data on patients receiving 
the 0.25 mg/kg tenecteplase dose or 0.9 mg/kg alteplase, and excluded the 0.1mg/kg group. A 
key inclusion criteria difference between the two trials was that for Australia-TNK, patients 
were required to have a ‘dual-target’: visible CTP mismatch (by qualitative assessment), and 
an intracranial vessel occlusion on CTA (excluding internal carotid artery occlusions). 
ATTEST used standard of care NCCT thrombolysis eligibility, but obtained multimodal CT 
imaging (CTP and CTA) following randomisation. Initial stroke severity evaluated by NIHSS 
score was measured in all patients acutely and at 24 hours, while resulting disability was 
assessed using the modified Rankin Scale (mRS, range 0-6 0 being no disability and 6 being 
death) at 90 days in a blinded fashion. These studies were approved by the local institutional 
review committees and each participant provided written informed consent. 
 
Imaging acquisition 
For both studies baseline computed tomography (CT) imaging included non-contrast 
CT (NCCT), CT perfusion (CTP) and CT angiography (CTA) with at least 80mm of 
coverage. Follow-up NCCT and CTA were performed with the same acquisition as the 
baseline scan in ATTEST and at 24-48 hours after thrombolysis. Follow-up imaging for the 
Australia-TNK study were on 1.5T or 3T MRI scanners (Siemens Avanto, or Skyra). MRI 
sequences included an axial gradient-echo T2*-weighted series, diffusion-weighted imaging 
(DWI), magnetic resonance angiography (MRA), perfusion weighted imaging (PWI) and 
flow-attenuated inversion recovery (FLAIR).   
 
Pooled imaging analysis 
CT perfusion is able to identify both critically ischemic tissue and established 
infarction using thresholds of ischemia.4 The optimal measures have been validated against 
magnetic resonance imaging.5 The delay in the time it takes for blood to reach a particular 
region is used to identify ischemia (delay time), and the severity in the reduction of blood 
flow is used to identify ischemic core (cerebral blood flow). Individual patient imaging was 
centrally analysed with commercial software (MIStar, Melbourne, Australia), blind to clinical 
status and treatment allocation. Image analysis was performed by two stroke neurologists and 
a clinical scientist. All perfusion imaging was processed using the singular value 
deconvolution (SVD) algorithm with delay and dispersion correction6 to generate maps of 
cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT) and 
delay time (DT). This algorithm provides more accurate measures of infarct core and 
penumbra than other commonly used methods.7 Next, validated thresholds to measure the 
baseline penumbra and ischemic core volume applied. The perfusion lesion was defined as 
tissue with a delay time (DT) of >3 seconds and the ischemic core as tissue within the 
perfusion lesion (DT>3sec) but with a cerebral blood flow of <30% of normal tissue as 
determined from SVD output8. The penumbra was defined as tissue within the perfusion 
lesion but not within the ischemic core (DT>3sec, CBF >30%).9,10 The mismatch ratio was 
determined as the ratio of the perfusion lesion volume (DT>3sec) to the volume of the 
ischemic core (DT>3sec, CBF<30%). Severe hypoperfusion was defined as DT>8 seconds. 
All baseline CTA were assessed centrally for occlusion status and site of occlusion. 
The studies originally used slightly differing methods to define baseline vessel occlusion and 
vessel recanalization at 24-48 hours. For the pooled analysis we classified baseline occlusion 
status as either (i) normal, (ii) partial (using dynamic CTP source images to confirm/exclude 
residual antegrade flow by assessing if distal arterial branches filled with contrast prior to 
immediately beyond the occlusion), or (iii) complete occlusion (no antegrade flow).11 
Patients with normal baseline CTA were not included in the recanalization assessments.  
Brain haemorrhage outcomes were the occurrence of any parenchymal hematoma 
(PH), and large PH (PH2), as defined by the Second European-Australasian Acute Stroke 
Study (ECASS-2). We defined symptomatic intracranial haemorrhage (sICH) according to 
the Safe Implementation of Thrombolysis in Stroke Monitoring Study12 as PH2 accompanied 
by neurological deterioration by ≥4 points on the NIHSS.  
 
Imaging mismatch classification 
We then classified patients as having target mismatch or no target mismatch based on 
whether they met target mismatch criteria (absolute mismatch volume >15mL, mismatch 
ratio >1.8, baseline ischemic core <70mL, and volume of severely hypoperfused tissue 
<100mL)13. Penumbral salvage was defined as the proportion of baseline penumbra that did 
not progress to infarction on 24-48 hour NCCT (ATTEST) or 24 hour DWI (Australia-TNK). 
Infarct growth was defined as the growth from baseline CTP ischemic core (DT>3sec, 
CBF<30%) volume to 24-48 hour NCCT or 24 hour DWI. 
  
Clinical-core Mismatch classification 
Using the mismatch criteria from the DAWN trial14, patients were classified into one 
of three categories. Category A was patients 80 years of age or older, a score of 10 or higher 
on NIHSS, and CTP ischemic core volume of less than 21 ml. Those in Category B were 
younger than 80 years of age, had a score of 10 or higher on the NIHSS, and an ischemic core 
volume of less than 31 ml on CTP. Those in Group C were younger than 80 years of age, had 
a score of 20 or higher on the NIHSS, and had an infarct volume of 31 to less than 51 ml on 
CTP. 
 
Statistical analysis 
Statistical analysis was performed using Stata version 14. Firstly, we compared 
between trials the baseline clinical and reprocessed imaging data of Australia-TNK and 
ATTEST using Wilcoxon rank-sum test and Fisher exact tests where appropriate. We also 
compared the patient characteristics between the mismatch categories using Wilcoxon rank-
sum test and Fisher exact tests where appropriate. Next, patients were categorized as either 
having imaging mismatch and/or clinical mismatch. We then compared the clinical outcomes 
of patients receiving either tenecteplase 0.25mg/kg or alteplase 0.9mg/kg between mismatch 
categories separately for patients with imaging mismatch or clinical mismatch using a fitted a 
logistic regression model to calculate the odds ratio of mRS 0-1, mRS 0-2, and mRS 5-6.  
Imaging outcomes were rates of brain haemorrhage (any PH, PH2, and sICH), penumbral 
salvage, infarct growth, and recanalization. Clinical characteristics compared included the 
baseline, 24 hour and change in NIHSS, patient age and time to treatment.  
 
Results 
The 96 patients from the ATTEST per protocol analysis and 50 from the Australian-
TNK study were pooled for a combined analysis on 146 patients who were randomized to 
either 0.25 mg/kg tenecteplase or 0.9 mg/kg alteplase. Seventy-one patients received alteplase 
and 74 received tenecteplase. There were considerable differences in baseline imaging 
characteristics between the patients in each trial, however there were no significant 
differences between pooled treatment groups (table 1). In the pooled cohort with no mismatch 
selection applied (i.e. all patients), those treated with tenecteplase did not have better 3-month 
outcomes (mRS 0-1 OR 1.77, 95% CI 0.89-3.51, p=0.102). However, in the total pooled 
cohort there were significant differences in patients treated with tenecteplase in terms of the 
NIHSS change from baseline to 24 hours (tenecteplase 5.26 vs alteplase 2.44, p=0.016), the 
rate of recanalization (tenecteplase 68% vs alteplase 27%, p<0.001) and infarct growth 
(tenecteplase 12mL vs alteplase 23mL, p=0.027). Notably, 76 (52%) patients had a large 
vessel occlusion (70 or 49% with an M1 occlusion and 6 or 4% with an ICA occlusion).  
Pooled analysis (clinical-core versus target mismatch agreement). 
 From the pooled data, a total of 39 (27%) patients met both the clinical-core and 
target mismatch criteria, 25 (17%) patients met the target mismatch but not the clinical-core 
mismatch criteria, 36 (26%) did not meet the target mismatch but did meet the clinical-core 
mismatch criteria, and finally 46 (32%) did not meet either of the imaging or mismatch 
criteria. Of the 25 patients who met the target mismatch but not the clinical-core mismatch 
criteria, 12 (48%) had a baseline NIHSS <10, and 13 (52%) had a baseline infarct core 
volume above the age-related clinical-core mismatch criteria. The median 3-month mRS of 
patients who met the target mismatch but not the clinical-core mismatch criteria was 3 (range 
0-4 table 4). In the 36 patients that did not meet the target mismatch but did meet the clinical-
core mismatch criteria, 26 (72%) had a baseline perfusion lesion below 15mL, with the 
remaining 10 (28%) having a mismatch ratio <1.8. The median mRS of patients who met the 
clinical-core but not the target mismatch criteria was 2 (range 0-4).  
 Of patients meeting both imaging and clinical mismatch (N=39), tenecteplase resulted 
in significantly improved rates of excellent 90 day clinical outcome (mRS 0-1, OR 2.61, 95% 
CI 6.81-1.34, p=0.018, figure 1). Patients not meeting any mismatch criteria had the highest 
rate of PH (mismatch 7%, non-mismatch 13%, p=0.044) and the lowest NIHSS change from 
baseline to 24 hours (mismatch 7, non-mismatch 2, p=0.037). Additionally, patients without 
clinical and imaging mismatch had a lower rate of complete vessel occlusion at baseline 
(mismatch 63%, non-mismatch 21%p<0.001) and recanalization at 24 hours (mismatch 41%, 
non-mismatch 19%, p<0.001).  
 
Pooled analysis (clinical-core mismatch patients): tenecteplase vs alteplase. 
75 of the 146 patients fulfilled clinical-core mismatch criteria, with 39 receiving 
tenecteplase and 32 alteplase. Of the three clinical-core mismatch categories, the majority (59 
patients, 79%) of patients were in category B (NIHSS >9, age <80 yo and infarct core 
<31mL), followed by 14 patients (18%) in category A (NIHSS >9, age >80yo and infarct 
core <21mL), and only 2 (3%) in category C (NIHSS >9, age <80yo and infarct core, 31mL- 
51mL). Patients with clinical-core mismatch had significantly higher odds of achieving an 
excellent clinical outcome when treated with tenecteplase over alteplase (mRS 0-1 OR 2.15, 
95% CI 1.1428.732, p=0.027, table 2, but not good clinical outcome (mRS 0-2 OR 2.296, 
95% CI 0.882-5.978, p= 0.089), or poor clinical outcome (mRS 5-6 OR 0.495, OR, 95% CI 
0.127-1.936, p=0.312) Clinical-core mismatch patients treated with tenecteplase had greater 
early clinical improvement (median NIHSS change, tenecteplase 8 versus alteplase 3, 
p=0.012), and tended to have less PH (tenecteplase 5% vs alteplase 12%, p=0.207). Clinical 
mismatch patients treated with tenecteplase also had higher recanalization rates (tenecteplase 
59% vs alteplase 19%, p<0.001) and less infarct growth (tenecteplase 25mL vs alteplase 
32mL, p=0.036, table 2).  
Of the 71 patients not fulfilling clinical-core mismatch criteria, 38 (53%) patients with 
age >80 were excluded due to baseline ischemic core volume >21 mL, the median being 27 
mL (SD). Fourteen patients less than 80 years old (20%) were excluded due to a larger 
ischaemic core (>51mL). Patients not fulfilling clinical mismatch who were treated with 
tenecteplase had significantly higher rates of complete recanalization with TNK (56% TNK 
vs 17% rtPA, p<0.001). However, compared to alteplase patients, tenecteplase patients 
without clinical-core mismatch did not have better rates of excellent clinical outcome (mRS 
0-1 0.973, OR, 95% CI 0.357-2.651, p= 0.357), good clinical outcome (mRS 0-2 0.92, OR, 
95% CI 0.37-2.659, p= 0.598), or poor clinical outcome (mRS 5-6 1.021, OR, 95% CI 0.323-
3.229, p= 0.472). Tenecteplase patients without clinical-core imaging mismatch did not have 
less infarct growth (tenecteplase 22mL vs alteplase 10mL, p=0.206), although, again, rate of 
PH did tend to be lower (tenecteplase 5% vs alteplase 16%, p=0.163). 
 
Pooled analysis (target mismatch patients): tenecteplase vs alteplase. 
Seventy four of the 146 patients fulfilled perfusion-core target mismatch criteria, with 
33 receiving tenecteplase and 35 alteplase. Patients treated with tenecteplase with target 
mismatch had significantly higher odds of achieving an excellent clinical outcome (mRS 0-1, 
OR 2.33, 95% CI 1.13-5.94, p<0.001, table 3), good clinical outcome (mRS 0-2 1.92, OR, 
95% CI 1.21-8.87, p= 0.033), and lower rates of poor clinical outcome (mRS 5-6 0.3, OR, 
95% CI 0.09-0.87, p=0.012). Target mismatch patients treated with tenecteplase had greater 
early clinical improvement (median NIHSS change, tenecteplase 6, alteplase 1, p<0.001). 
Target mismatch patients treated with tenecteplase also had higher recanalization rates (90% 
tenecteplase vs 33% alteplase, p<0.001) and less infarct growth (1.2mL tenecteplase vs 
18.3mL alteplase, p<0.001).  
Of the 72 patients not fulfilling imaging mismatch criteria, 62(86%) were excluded 
due to an absolute penumbral volume <15 mL, the majority being <10 mL (78%, 56/72). 
Seven patients (10%) were excluded due to a large ischaemic core (>70mL). It was 
noteworthy that the majority of excluded patients (45/72, 63%) still had a baseline vessel 
occlusion. Despite much better complete recanalization with tenecteplase (83% vs 41% rtPA, 
p-0.006), there were no differences in the rate of excellent clinical outcome (mRS 0-1, OR 
0.86, 95% CI 0.32-2.24, p=0.751), good clinical outcome (mRS 0-2, 0.71 OR, 95% CI 0.28-
1.80, p=0.471), or poor clinical outcome (mRS 5-6, OR 1.46, 95% CI 0.30-7.06, p=0.342) in 
tenecteplase versus alteplase patients without target mismatch. Lastly, patients without target 
mismatch did not have less infarct growth (7 mL vs 12.6mL alteplase, p=0.544), or lower 
rates of PH (tenecteplase 6% vs alteplase 8%, p=0.692) with tenecteplase. 
 
Discussion 
In the present analysis we have demonstrated that in a pooled population comprising 
of two randomised tenecteplase versus alteplase trials, that tenecteplase results in 
significantly better clinical outcomes regardless of the mechanism of ‘mismatch’ selection. 
Additionally, we compared the effect size and impact of two different mismatch criteria on 
the results from randomised trial data comparing tenecteplase to alteplase and found that 
patient selection with target mismatch resulted in a larger treatment effect compared to 
clinical-core mismatch selection. Moreover, target mismatch selection resulted in a lower 
proportion of haemorrhages and poor clinical outcome in the tenecteplase treated group (but 
not in the clinical-core mismatch selected group).  
Importantly, these results demonstrate that applying patient selection to a trial dataset 
substantially increases the power to detect a treatment effect groups (if there is one). This is 
evident as roughly one half of the patient cohort was excluded from some analysis due to 
failure to meet any criteria, yet the overall results still showed a statistically significant result 
for treatment benefit of tenecteplase over alteplase. Without such mismatch criteria, it may be 
necessary to have a substantially larger sample size which could potentially take much longer 
to collect. The criteria which mostly prevented patient inclusion as clinical-core mismatch 
was the NIHSS cut off of 10. This cut-off ensures that patients have a substantial acute 
clinical deficit, yet does not provide data on the tissue status of patients, such as occlusion 
location, perfusion lesion volume or ischemic core volume. For thrombectomy, confirmation 
of a large vessel occlusion would be required, however when considering intravenous 
thrombolysis, visible occlusion is not mandatory. Therefore, the NIHSS cut-off in clinical-
core mismatch criteria excludes a substantial number of patients with ‘mild’ stroke who may 
benefit from thrombolysis, and as such the generalisability of this classification may be 
limited. However, both the clinical and imaging mismatch approaches resulted in an overall 
treatment responsive result to thrombolysis with tenecteplase compared against alteplase, and 
less poor outcomes using the target mismatch approach.  
In conclusion, we have demonstrated that patient selection with a mismatch approach 
provides greater power to detect change for reperfusion therapy clinical trials but selecting 
the more severe end of patients on the ischemic stroke spectrum. Moreover, target mismatch 
based selection appeared to be more inclusive for a thrombolysis cohort (more generalizable) 
and exhibited in a larger treatment effect between the two interventions.  
 
 
 
 
 
 
 
 
 
 
 
  
 
Comparison between treatment groups 
Baseline clinical Characteristics 
  tenecteplase n=75 alteplase n=71 p value 
Median age (years, IQR) 72 (17) 73 (19) 0.225 
Median symptom onset to 
imaging (mins, IQR) 
170 (73) 169 (81) 0.621 
Median symptom onset to 
Treatment time (mins, 
IQR) 
180 (61) 186 (68) 0.445 
Median acute NIHSS 
(IQR) 
13 (7) 12 (7) P=0.572 
Hypertension (%) 32% 30% 0.884 
Diabetes Mellitus (%) 30% 23% 0.441 
Hyperlipidaemia (%) 30% 23% 0.441 
Atrial Fibrillation at 
admission 
36% 24% 0.187 
Anti-platelets  58% 55% 0.906 
Median baseline ischaemic 
core volume (mL, IQR) 
10 (19) 12 (27) 0.409 
Median baseline perfusion 
lesion volume (mL, IQR) 
26 (58) 28 (64) 0.578 
Median baseline mismatch 
ratio (IQR) 
1.98 (2.18) 2.05 (2.35) 0.509 
Excellent outcome (mRS 0-
1) 
19 (61%) 
 
13 (36%) 
 
2.15 (1.14, 
8.73) p=0.027 
Good outcome (mRS 0-2) 20 (64%)  
 
15 (49%) 2.29 (0.88-
5.97) p=0.089 
Poor outcome (mRS 5-6) 8  (23%) 8 (22%) 0.49 (0.12-
1.93) p=0.312 
Early clinical 
improvement (median 
reduction in acute-24 hour 
NIHSS, 95th centiles in 
brackets) 
7 (-4,14) 2 (-6, 11) P=0.012 
Any PH 2 (6%) 5 (16%) p<0.001 
Complete recanalization 56% 17% p<0.001 
Table 1. A comparison of baseline clinical and imaging data between the teneteplase and 
alteplase treated patients in the pooled analysis. Occlusion site reports the source location of 
hypo-perfusion and does not represent occlusion severity. IQR- Interquartile range. NIHSS – 
National Institutes of Health Stroke Scale. mRS –Modified Rankin score. ICA – Internal 
carotid artery. M1 – Middle cerebral artery. ACA – Anterior cerebral artery. PCA- posterior 
cerebral artery. 
 
 
 
 
 
Comparison between treatment groups in patients meeting the clinical mismatch 
criteria  
Clinical Outcomes 
 Teneteplase 
n= 39 
alteplase  
n= 32 
Odds ratio (95th CI), 
and/or p value 
Early clinical improvement 
(median reduction in acute-24 
hour NIHSS, 95th centiles in 
brackets) 
8 (-6,14) 3 (-5,13) p=0.012 
Excellent outcome (mRS 0-1) 
 
20 (51%) 9 (28%) 2.15 (1.14, 28.73) 
p=0.027 
Good outcome (mRS 0-2) 
 
24 (61%) 13 (38%) 2.29 (0.88-5.97) p= 0.089 
Poor outcome (mRS 5-6) 9 (23%) 11 (38%) 0.49 0.127-1.936, 
p=0.312 
Imaging Outcomes  
 Teneteplase 
n= 39 
alteplase  
n= 32 
Odds ratio (95th CI), 
and/or p value 
Any PH 2 (5%) 3 (12%) p=0.207 
Complete recanalization 
 
23 (59%) 6 (19%) p<0.001 
Table 2, a comparison of the clinical and imaging efficacy of tenecteplase compared to 
alteplase in patients who met clinical mismatch criteria. 
Comparison between treatment groups in patients meeting the imaging mismatch 
criteria 
Clinical Outcomes 
 Teneteplase 
n= 40 
alteplase  
n=34 
Odds ratio (95th CI), 
and/or p value 
Early clinical improvement 
(median reduction in acute-24 
hour NIHSS, 95th centiles in 
brackets) 
9 (-5,14) 1 (-9, 11) p<0.001 
Excellent outcome (mRS 0-1) 21 (53%) 8 (24%) 2.33 (1.31, 5.94) p<0.001 
Good outcome (mRS 0-2) 26 (65%)  12 (35%) 1.92 (1.21, 8.87) p=0.03 
Poor outcome (mRS 5-6) 5  (13%) 11 (32%) 0.30 (0.09, 0.87) p=0.04 
Imaging Outcomes  
 Teneteplase 
n= 40 
alteplase  
n=33 
Odds ratio (95th CI), 
and/or p value 
Any PH 0 (0%) 7 (21%) p=0.003* 
Complete recanalization 
 
35/39 
(90%) 
10/30 
(33%) 
p<0.001 
Table 3, a comparison of the clinical and imaging efficacy of tenecteplase compared to 
alteplase in patients who met imaging mismatch criteria. 
 
 Imaging 
and clinical 
mismatch 
Imaging but 
not clinical 
mismatch 
Clinical but 
not imaging 
mismatch 
No imaging 
or clinical 
mismatch 
N 39 25 36 46 
Baseline NIHSS (median, 
95th centiles)  
15 (10-20) 10 (4-20) 13 (10-24) 9 (2-25) 
24h NIHSS(median, 95th 
centiles) 
7 (-1-23) 5 (-2-27) 5 (-4-35) 7 (-8-29) 
Day 90 outcomes 
mRS 0-1 
mRS 0-2 
mRS 5-6  
 
38% 
58% 
21% 
 
32% 
49% 
32% 
 
36% 
55% 
28% 
 
31% 
44% 
20% 
Age (median, 95th 
centiles) 
72 (55-80) 79 (48-94) 71 (46-80) 68 (43-85) 
Time to treatment 
(median, 95th centiles) 
174 (102-
246) 
200 (115-
295) 
180 (107-
264) 
183 (110-261) 
Any PH 8% 4% 8% 13% 
Complete recanalization 
% 
46% 44% 31% 19% 
Table 4, The imaging and clinical outcome measures of patients who met either clinical 
and/or imaging mismatch criteria. 
 
 
 
 
 
 Figure 1, A Box Forrest plot showing the impact of treatment mismatch selection criteria on 
the treatment effect of tenecteplase compare to alteplase in ischemic stroke patients. 
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